Giuseppina Fugazza

Genoa, 16132, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment.

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment.

Journal: Antibodies (Basel, Switzerland)

Published: August 11, 2025

Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.

Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.

Journal: Hematological oncology

Published: September 13, 2024

Establishment and Characterization of a Novel Fibroblastic Cell Line (SCI13D) Derived from the Broncho-Alveolar Lavage of a Patient with Fibrotic Hypersensitivity Pneumonitis.

Establishment and Characterization of a Novel Fibroblastic Cell Line (SCI13D) Derived from the Broncho-Alveolar Lavage of a Patient with Fibrotic Hypersensitivity Pneumonitis.

Journal: Biomedicines

Published: July 27, 2021

A novel mutation of Twinkle in Perrault syndrome: A not rare diagnosis?

A novel mutation of Twinkle in Perrault syndrome: A not rare diagnosis?

Journal: Annals of human genetics

Published: November 21, 2019

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Journal: British journal of haematology

Published: January 24, 2018

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

Journal: American journal of hematology

Published: December 24, 2015

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Journal: Leukemia research

Published: November 05, 2014

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.

Journal: Leukemia research reports

Published: April 10, 2013

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Journal: Leukemia research

Published: February 01, 2013

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

Journal: Current cancer drug targets

Published: November 21, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026